sIPV batch 1
ApprovedBiologic
sIPV batch 1 is one of 11 biologic programs targeting Poliomyelitis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Poliomyelitis
#DrugCompanyPhaseTrials
1Comparator: Pbo
Merck & Co.Phase 3
Rotateq
Merck & Co.Phase 3
Hepatitis B Vaccine
SanofiPhase 2
Inactivated Rabies Virus Vaccine
SanofiPhase 2
sIPV batch 1
IInstitute of Medical Biology, Chinese Academy of Medical Sciences
Approved
Sipv
Sinovac Biotech Co., LtdApproved
Concomitant Administration
SanofiPhase 3
Oral NVB Metronomic
SanofiPhase 2
Verazinc
FFakultas Kedokteran Universitas Indonesia
Preclinical
Poliorix.
GSKPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Poliomyelitis1 trial
Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain
Completed·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 4·NCT04224519·1,200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sIPV batch 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details